FDA approves Fast Track designation for bemcentinib in AML indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved Fast Track designation for bemcentinib for treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login